Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
VALTREX (valacyclovir hydrochloride) is an oral antiviral small molecule approved in 1995 for treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It is a prodrug of acyclovir that inhibits viral DNA polymerase, reducing viral replication and symptom duration. This drug serves as a standard-of-care treatment for genital herpes, cold sores, and shingles across multiple patient populations.
Brand is in late-stage lifecycle with modest Medicare spending; commercial teams are likely focused on generic transition planning and niche patient retention rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Worked on VALTREX at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moVALTREX offers limited job openings (0 linked roles identified) and represents a stabilization or wind-down career assignment rather than a growth opportunity. Professionals should expect work focused on protecting market share, negotiating generic agreements, and transitioning commercial infrastructure post-LOE.